CentralReach, the leading provider of autism and intellectual and developmental disability software for applied behavior analysis and multidisciplinary providers, recently announced the appointment of David Stevens to the new role of head of GenerativeAI.
In this role, he will ramp up the Holmdel-based firm’s GenAI investments and tools, offering the only fully integrated, real-time revenue cycle management audit capability in the industry.
The company currently has over 20 embedded GenAI solutions either in design, pilot, beta or production, with a strong pipeline of solutions to follow, and, with this new appointment, Stevens will spearhead CentralReach’s AI initiatives to help unlock cashflow and improve therapy delivery for customers using CentralReach’s Autism and IDD Care Platform, activating on high-impact opportunities and delivering tangible benefits unmatched by any competitor or third-party solution.
This news comes a few short months after the company announced its decision to increase investments in GenAI and introduce its GenAI assistant “cari.” The new AI assistant powers solutions across CentralReach’s suite of solutions and leverages information from the company’s unparalleled proprietary data set to produce recommendations for review, such as automated session summaries, 24/7 clinical test prep support, fast-tracked assessment recommendations, optimized staffing and schedule recommendations and more.
“In every discussion we have with our customers and other industry players, navigating capacity constraints and employee turnover as well as increasing workflow complexity is top of mind for providers large and small,” Chris Sullens, CEO of CentralReach, said. “The significant investments we continue to make are designed to leverage our unparalleled data set, our talented thought leaders, subject matter experts and our position as the market leader in autism and IDD care to create fully integrated solutions that use GenAI to simplify workflows, provide unique business insights and increase margins and cash flow for our users.
“Every conversation to date has reinforced our hypothesis that the ABA industry sees GenAI, deployed responsibly and thoughtfully, as a help and not a threat because it allows them to serve more individuals while realizing improved economics.
“By appointing Dave, a proven entrepreneurial leader, to spearhead our initiatives and align our roadmap with high-impact opportunities such as AI-generated session notes, real-time AI-supported claims verification and AI-supports for RBT supervision, we are delivering tangible benefits unmatched by any competitor or third-party solution. The feedback from users to-date has been amazing and I’m excited to get these into market and begin to pilot the many exciting solutions we have in the pipeline.”
